Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 117

Sort by

Sort Order Select

Journal Articles

Outcomes after Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based Therapies

Keith W. Pratz, MD, Courtney D. DiNardo, MD MSc, Martha L. Arellano, MD, Anthony G. Letai, MD PhD, Michael Thirman, MD, Vinod A. Pullarkat, MD, Gail J. Roboz, MD, Pamela S. Becker, MD PhD, Wan-Jen Hong, MD, Qi Jiang, John Hayslip, MD MSCR, Jalaja Potluri, MD, Daniel A Pollyea, MD

Blood (2019) 134 (Supplement_1): 264.

https://doi.org/10.1182/blood-2019-127251

Published: 2019

Journal Articles

Final Analysis of GOYA: A Randomized, Open-Label, Phase III Study of Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Laurie H Sehn, MD, Maurizio Martelli, MD, Marek Trněný, MD, Wenxin Liu, PhD, Christopher R Bolen, PhD, Andrea Knapp, PhD, Deniz Sahin, BSc, Gila Sellam, PhD, Umberto Vitolo

Blood (2019) 134 (Supplement_1): 4088.

https://doi.org/10.1182/blood-2019-123433

Published: 2019

Journal Articles

Safety and Efficacy of Ibrutinib in Combination with Venetoclax in Patients with Marginal Zone Lymphoma: Preliminary Results from an Open Label, Phase II Study

Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, Amit Khot, MBBS, MD MRCP, FRCPath, FRACP, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Piers Blombery, MBBS, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, David Ritchie, MD PhD, Rodney J. Hicks, MB BS (Hons), MD FRACP, FAHMS, Besiat Birbirsa, B.N., Mathias Bressel, M.Sc, Juliana Di Iulio, PhD, David Alan Westerman, MBBS, FRCPA, FRACP, Stephen Lade, MBBS, FRCPA, Andrew W. Roberts, MBBS, PhD, John F. Seymour, MBBS, PhD FRACP, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 3999.

https://doi.org/10.1182/blood-2019-126396

Published: 2019

Journal Articles

Effect and Safety of Ixazomib Plus Dexamethasone (ID) in Patients with Waldenstrom's Macroglobulinemia (WM): Real-World Evidences from a Single Center in China

Jiadai Xu, Zheng Wei, MD, Jing Li, MD, Jingli Zhuang, Lili Ji, Peng Liu, MD

Blood (2019) 134 (Supplement_1): 5265.

https://doi.org/10.1182/blood-2019-128816

Published: 2019

Journal Articles

Randomized Phase 2 Zanubrutinib (BGB-3111) + Obinutuzumab Vs Obinutuzumab Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL)

Nathan H. Fowler, MD, Judith Trotman, MBChB, FRACP, FRCPA, Rebecca Auer, MRCP, FRPath, PhD, Christopher R. Flowers, MD MS, William F. Reed, MD, Elena Ivanova, PhD, Jane Huang, MD, Pier Luigi Zinzani, MD PhD

Blood (2019) 134 (Supplement_1): 5252.

https://doi.org/10.1182/blood-2019-122628

Published: 2019

Journal Articles

The Efficacy and Safety of Cidofovir in Salvage Therapy for CMV Infection in the Patients with Haploid Hematopoietic Stem Cell Transplantation

Guo-Pan Yu, MD, Zhao Yin, Zhiping Fan, Fen Huang, Na Xu, Ling Jiang, Zhixiang Wang, PhD, Li Xuan, MD, Qifa Liu, MD, Ru Feng, MD, Jing Sun

Blood (2019) 134 (Supplement_1): 5659.

https://doi.org/10.1182/blood-2019-126705

Published: 2019

Journal Articles

Bispecific T-Cell Engager (BiTE) Antibody Based Immunotherapy for Treatment of Relapsed Refractory Multiple Myeloma (RRMM): A Systematic Review of Preclinical and Clinical Trials

Zunairah Shah, MBBS, Mustafa Nadeem Malik, MD, Syeda Sabeeka Batool, MBBS, MD, Sravanthi Kotapati, MBBS, Aisha Akhtar, MBBS, Owais ur Rehman, MBBS, Marium Ghani, MBBS, Maryam Sadiq, MBBS, Arshia Akbar, MD, Aqsa Ashraf, MBBS, Arafat Ali Ali Farooqui, MD, Muhammad Abdullah Yousaf, MBBS, MD, Muhaddis Ejaz Ahmad, MD, Hafiz Muhammad Fazeel, MBBS, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5567.

https://doi.org/10.1182/blood-2019-129652

Published: 2019

Journal Articles

Phase 2 Study of Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Stephen Opat, Robert Marcus, MA, FRCP, FRCPath, Craig A. Portell, MD, William Reed, MD, Chris Tankersley, Jane Huang, MD, Judith Trotman, MBChB, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 5256.

https://doi.org/10.1182/blood-2019-122629

Published: 2019

Journal Articles

Depth of Response and Response Kinetics in the Icaria-MM Study of Isatuximab with Pomalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Cyrille Hulin, MD, Paul G. Richardson, MD, Michel Attal, MD PhD, Hugh J. Goodman, FRACP, Vadim A Doronin, MD, Ivan Spicka, MD PhD Prof, Solenn Le-Guennec, Frank Campana, MD, Helgi van de Velde, MD PhD, Meral Beksac, MD

Blood (2019) 134 (Supplement_1): 3185.

https://doi.org/10.1182/blood-2019-129840

Published: 2019

Journal Articles

Long-Term Outcomes and Organ Responses with Daratumumab Therapy in Previously Treated Patients with AL Amyloidosis

Alfred Chung, MD, Gregory P. Kaufman, MD, Surbhi Sidana, MD, Erik Eckhert, MD MS, Stanley Schrier, MD, Sally Arai, MD, Richard Lafayette, MD, Ronald Witteles, MD, Michaela Liedtke, MD

Blood (2019) 134 (Supplement_1): 1828.

https://doi.org/10.1182/blood-2019-122152

Published: 2019

Journal Articles

Towards Higher Safety of Haemato-Oncological Patients Undergoing Treatment

Tereza Popkova, MD, Katarina Hradska, MD, Jana Mihalyova, MD, Michaela Skorupova, Tomas Jelinek, MD, Juraj Duras, MD, Zdenek Koristek, MD PhD, Milan Navratil, MD, Katerina Benkova, MD, Hana Plonkova, MD, Jana Zuchnicka, MD, Jaromir Gumulec, MD, Roman Hajek, Prof, MD PhD

Blood (2019) 134 (Supplement_1): 4757.

https://doi.org/10.1182/blood-2019-127011

Published: 2019

Journal Articles

Econsultation to Hematologists from Primary Care: An Assessment of Content and Patient Impact

Megan Leslie, BS, Sa Ra Park, MD, Jennifer Wang, MD, Kelly Mercer Davidson, MD, Kimberly Dowdell, MD

Blood (2018) 132 (Supplement 1): 2279.

https://doi.org/10.1182/blood-2018-99-114149

Published: 2018

Journal Articles

Danazol Treatment for Thrombocytopenia in Lower-Risk Myelodysplastic Syndromes: A Pilot Real Life Experience

Marta Riva, Lara Crucitti, Emanuele Ravano, MD, Michele Nichelatti, PhD, Gianluigi Reda, MD, Cristina Fiamenghi, Roberto Cairoli, Alfredo Molteni, MD

Blood (2018) 132 (Supplement 1): 4375.

https://doi.org/10.1182/blood-2018-99-115283

Published: 2018

Journal Articles

The Predictive Value of Thromboelastogram in the Evaluation of Patients with Suspected Acute Venous Thromboembolism

Tareq Abu Assab, MD, David Raveh-brawer, MD, Julia Abramowitz, Mira Naamad, Jacob M. Rowe, MD, Chezi Ganzel, MD

Blood (2018) 132 (Supplement 1): 5052.

https://doi.org/10.1182/blood-2018-99-119466

Published: 2018

Journal Articles

Necrotic but Not Apoptotic Platelets Are Functionally Procoagulant

Andaleb Kholmukhamedov, MD, Shawn M. Jobe, MD PhD

Blood (2018) 132 (Supplement 1): 2420.

https://doi.org/10.1182/blood-2018-99-116972

Published: 2018

Journal Articles

Ibrutinib Increases the Clonality of TCR Repertoire in Patients with Chronic Lymphocytic Leukemia

Maria Joao Baptista, PhD PharmD, Neil Basumallik, Sarah E. M. Herman, PhD, Erika M. Cook, Inhye E. Ahn, MD, Adrian Wiestner, MD, Clare C. Sun, MD

Blood (2018) 132 (Supplement 1): 238.

https://doi.org/10.1182/blood-2018-99-109847

Published: 2018

Journal Articles

Measuring the Anticoagulation Effects of Exosite I Thrombin Inhibitors: Utility and Limitations of Clotting Assays, Thromboelastography, and Calibrated Automated Thrombography

Matthew Bunce, PhD, Zheng Huang Devine, PhD, Madhu Chintala, PhD

Blood (2017) 130 (Supplement 1): 1115.

https://doi.org/10.1182/blood.V130.Suppl_1.1115.1115

Published: 2017

Journal Articles

KI Intolerance Study: A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib (TGR-1202) in Patients with Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK or PI3K-δ Inhibitor Therapy

Blood (2017) 130 (Supplement 1): 4314.

https://doi.org/10.1182/blood.V130.Suppl_1.4314.4314

Published: 2017

Journal Articles

Daratumumab (DARA) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) in Patients with Newly Diagnosed Multiple Myeloma (MMY1001): Updated Results from an Open-Label, Phase 1b Study

Ajai Chari, Saad Z Usmani, MD, Amrita Krishnan, MD, Sagar Lonial, MD, Raymond Comenzo, Kaida Wu, Jianping Wang, Parul Doshi, Brendan M Weiss, MD, Jordan Schecter, Andrzej J. Jakubowiak, MD

Blood (2017) 130 (Supplement 1): 3110.

https://doi.org/10.1182/blood.V130.Suppl_1.3110.3110

Published: 2017

Journal Articles

MM-013 Phase 2, Multicenter Study of Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI): Pharmacokinetics (PK) Analysis

Pieter Sonneveld, MDPhD, Katja C. Weisel, Yan Li, Elisabeth Kueenburg, Shona Collins, Antonia Di Micco, Barbara Rosettani, Pamela Bacon, Meletios A. Dimopoulos

Blood (2017) 130 (Supplement 1): 1847.

https://doi.org/10.1182/blood.V130.Suppl_1.1847.1847

Published: 2017

NARROW

Outcomes after Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based Therapies

Final Analysis of GOYA: A Randomized, Open-Label, Phase III Study of Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Safety and Efficacy of Ibrutinib in Combination with Venetoclax in Patients with Marginal Zone Lymphoma: Preliminary Results from an Open Label, Phase II Study

Effect and Safety of Ixazomib Plus Dexamethasone (ID) in Patients with Waldenstrom's Macroglobulinemia (WM): Real-World Evidences from a Single Center in China

Randomized Phase 2 Zanubrutinib (BGB-3111) + Obinutuzumab Vs Obinutuzumab Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL)

The Efficacy and Safety of Cidofovir in Salvage Therapy for CMV Infection in the Patients with Haploid Hematopoietic Stem Cell Transplantation

Bispecific T-Cell Engager (BiTE) Antibody Based Immunotherapy for Treatment of Relapsed Refractory Multiple Myeloma (RRMM): A Systematic Review of Preclinical and Clinical Trials

Phase 2 Study of Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Depth of Response and Response Kinetics in the Icaria-MM Study of Isatuximab with Pomalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Long-Term Outcomes and Organ Responses with Daratumumab Therapy in Previously Treated Patients with AL Amyloidosis

Towards Higher Safety of Haemato-Oncological Patients Undergoing Treatment

Econsultation to Hematologists from Primary Care: An Assessment of Content and Patient Impact

Danazol Treatment for Thrombocytopenia in Lower-Risk Myelodysplastic Syndromes: A Pilot Real Life Experience

The Predictive Value of Thromboelastogram in the Evaluation of Patients with Suspected Acute Venous Thromboembolism

Necrotic but Not Apoptotic Platelets Are Functionally Procoagulant

Ibrutinib Increases the Clonality of TCR Repertoire in Patients with Chronic Lymphocytic Leukemia

Measuring the Anticoagulation Effects of Exosite I Thrombin Inhibitors: Utility and Limitations of Clotting Assays, Thromboelastography, and Calibrated Automated Thrombography

KI Intolerance Study: A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib (TGR-1202) in Patients with Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK or PI3K-δ Inhibitor Therapy

Daratumumab (DARA) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) in Patients with Newly Diagnosed Multiple Myeloma (MMY1001): Updated Results from an Open-Label, Phase 1b Study

MM-013 Phase 2, Multicenter Study of Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI): Pharmacokinetics (PK) Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only